During the last decades, the refinement of prekidney transplant risk immune monitoring and evaluation of the humoral arm of adaptive immunity has led to more effective kidney allocation and a dramatic reduction of posttransplant acute antibody-mediated rejection.^[@R1]-[@R3]^ However, T cell-mediated rejection (TCMR) unpredictably occurs, as no immune-risk stratification of cellular sensitization before transplantation is available in current clinical practice. Indeed, immunosuppressive protocols after kidney transplantation are generally adjusted on empirical bases and on a functional or histological evaluation of the allograft and/or signs of drug toxicity or infection.^[@R4]^ As a result, there are patients who are likely to receive too much or too little immunosuppression---exposing them to higher rates of infection, malignancy and drug toxicity, or conversely, to increased risk of acute and chronic graft rejection. Therefore, developing reliable biomarkers of antidonor T-cell alloimmune reactivity is crucial to individualize immunosuppressive therapy ultimately aimed at reducing allograft rejection risk, while minimizing adverse effects associated with over-immunosuppression.^[@R5]^

The interferon-γ enzyme-linked immunospot (IFN-γ ELISPOT) is an immune assay that has been developed and standardized in the field of transplantation as a way to functionally measure the number of circulating memory T cells with donor antigen reactivity.^[@R6],[@R7]^ While a number of single-center studies have reported a close association between positive pretransplant IFN-γ ELISPOT and increased risk of acute rejection (AR), particularly TCMR, and poor graft function at 6 and 12 months after transplantation,^[@R8]-[@R10]^ other studies have failed to identify such associations.^[@R11]^ Due to the high variability in patient characteristics and treatments across studies, we hypothesized that the IFN-γ ELISPOT performs differently in various patient populations and settings. Moreover, most published studies lack an acceptable balance regarding the predictive accuracy, which is a key for a biomarker to be used in the clinical practice.

To overcome these issues, we performed a meta-analysis of aggregate data from all published studies (including almost 1200 kidney transplant patients) evaluating the predictive performance of the pretransplant donor-specific IFN-γ ELISPOT as the most promising immune biomarker assessing the risk of TCMR in kidney transplant recipients. Our primary objective was to provide precise estimates of the predictive value of the pretransplant IFN-γ ELISPOT for AR at the individual level, taking into account all potential sources of heterogeneity across all the studies that may ultimately influence its predictive accuracy.

MATERIALS AND METHODS
=====================

Literature Search
-----------------

We performed a systematic literature search using the Cochrane Central Library, MEDLINE, and EMBASE databases up to October 2016 using a predefined algorithm (**Table S1, SDC**, <http://links.lww.com/TXD/A207>). Abstracts from proceedings of major conferences, International Clinical Trials Registry Platform Search Portal, and [ClinicalTrials.gov](http://ClinicalTrials.gov) were also searched. References included in pertinent systematic reviews were then screened. Studies were deemed eligible if they measured prekidney transplant donor-specific IFN-γ ELISPOT in patients who received a living- or deceased-donor kidney transplant alone. We excluded the studies if immunosuppression was modified on the basis of ELISPOT results.^[@R12]^ During screening, only articles written in English were included to prevent any misinterpretation of data. Study outcomes were not included as a part of the eligibility criteria.

All references were screened by 2 independent reviewers (S.F. and I.G.). If any discrepancies occurred, 2 additional reviewers were consulted (N.M. and O.B.). The study reviewers also examined reference lists of clinical practice guidelines, review articles, and relevant studies to identify missing articles and sent e-mails to investigators known to be involved in previous studies seeking information about unpublished or incomplete trials.

The protocol of this systematic review is published in the PROSPERO register (\#CRD42018116382).

Data Extraction, Outcomes, and Quality Assessment
-------------------------------------------------

Data extraction was independently performed by 3 reviewers (N.M., S.F., and I.G.) using standard data extraction forms. Reviewers were not blinded to authors, institutions, or article journals. If any discrepancies occurred, a consensus was reached after consulting a fourth investigator (O.B.).

Data extraction included the following characteristics of the studies: author's name, year of publication, number of included patients, duration of follow-up, donor and recipient demographics, and clinical characteristics. Outcomes were identified in the studies' text or tables. Data regarding death and graft loss were extracted from survival curves when necessary. The primary outcome was the incidence of AR (both clinically suspected and biopsy proven). Secondary outcomes were graft function (defined by estimated glomerular filtration rate \[eGFR\] and serum creatinine) and patient and graft survival.

Risk of Bias Assessment/Quality Assessment
------------------------------------------

We used Hayden criteria to estimate the bias of the included studies.^[@R13]^

This tool evaluates 6 domains as follows:

1.  Study participation: the study sample adequately represents the population of interest.

2.  Study attrition: the study data available (ie, participants not lost to follow-up) adequately represent the study sample.

3.  Prognostic factor (PF) measurement: the PF is measured in a similar way for all participants.

4.  Outcome measurement: the outcome of interest is measured in a similar way for all participants.

5.  Study confounding: important potential confounding factors are appropriately accounted for.

6.  Statistical analysis and reporting: the statistical analysis is appropriate, and all primary outcomes are reported.

Data Synthesis and Analysis
---------------------------

We presented the results from all studies using the original manufacturer scale for test interpretation. The IFN-γ ELISPOT value cutoff to define positivity in the majority of studies was 25 spots/3×10^5^ peripheral blood mononuclear cells (PBMCs),^[@R9],[@R11],[@R12],[@R14]-[@R18]^ though in 2 studies the cutoff was defined as 12 spots/3×10^5^ PBMCs.^[@R19],[@R20]^ In 1 study,^[@R18]^ we evaluated a cutoff of 25 spots/3×10^5^ PBMCs to homogenize all study data, as the cut-off was not explicitly defined.

We followed the Meta-analyses of Observational Studies in Epidemiology guidelines to report this systematic review and used Stata SE Release 15 (StataCorp, College Station, TX) for all analyses.^[@R21]^

We evaluated the association between pretransplant donor-specific IFN-γ ELISPOT and AR by calculating the odds ratio (OR) via random-effects meta-analysis. To overcome the presence of 0 cells in some of the 2×2 contingency tables, we added a small constant *ε* = 0.5 to all cells.^[@R22]^

To examine the predictive accuracy of pretransplant IFN-γ ELISPOT at the individual level, we performed a random-effects meta-analysis on sensitivity and specificity. Sensitivity represents the proportion of IFN-γ ELISPOT-positive patients who eventually developed AR, whereas specificity is the proportion of IFN-γ ELISPOT-negative patients who were AR free. To provide a joint pooled estimate of sensitivity and specificity which accounts for the correlation between the 2 parameters, we fitted a hierarchical summary receiver operating characteristic (ROC) model using the user-written Stata command *metandi.*^[@R23],[@R24]^ Using the command *metandplot*, we also plotted the model-fitted results, a summary ROC curve, a 95% confidence region, and a 95% prediction region (ie, confidence region for a forecast in a future study of the summary operating point of sensitivity and specificity).^[@R23],[@R24]^ Besides calculating the meta-analytic estimates of joined sensitivity and specificity, we also calculated the meta-analytic positive and negative likelihood ratios. These ratios can be interpreted as follows: a completely nonpredictive assay is reflected by a positive and negative likelihood ratio of 1; a slightly, moderately, and highly predictive assay is reflected by a positive likelihood ratio of above 2, 5, and 10 and by a negative likelihood ratio of below 0.5, 0.2, and 0.1, respectively.^[@R25]^

In an attempt to explain the reasons for heterogeneity across study findings concerning sensitivity and specificity and to identify patient categories in which pretransplant IFN-γ ELISPOT could be most useful, we additionally fitted metaregression models using the user-written Stata *metareg* command.^[@R26]^ These models were designed to examine to what extent sensitivity and specificity of IFN-γ ELSPOT could be affected by the type of induction therapy used (independent variable = % of thymoglobulin use), by ethnicity (% of African American recipients), by living- versus deceased-donor kidney transplantation (% of living donors), by era of study publication (year as continuous variable), and by geographical location of the study (indicator variable for North America, Asia, or Europe). To avoid inflating the rate of false-positive findings because of multiple testing, we referred to Monte Carlo permutation tests rather than the default nominal *P* values when declaring statistical significance (ie, 2-tailed, *P* \< 0.05) using the methodology proposed by Higgins and Thompson.^[@R27]^ However, in the meta-regression plots, we reported default nominal *P* values calculated by the default Knapp-Hartung variance estimator and associated *t* tests.^[@R28]^ For the purpose of meta-regression analyses, sensitivity and specificity were logit transformed. Sensitivity analyses were performed after the exclusion of the study published by our group.^[@R12]^ In this study, the type of immunosuppression was given according to the pretransplant IFN-γ ELSPOT. To see whether the inclusion of a study in which some patients underwent complete tacrolimus withdrawal might have accounted for inconsistencies between study findings, the analysis was repeated without this study (**Figure S1, SDC**, <http://links.lww.com/TXD/A207>).

Heterogeneity was analyzed using a chi-squared test on N−1 degrees of freedom, with an alpha of 0.05 used for statistical significance and the *I*^2^ test.^[@R27]^ The *I*^2^ statistic describes the percentage of total variation across studies that is due to heterogeneity rather than chance; *I*^2^ values of 25%, 50%, and 75% are indicative of low, moderate, and extreme heterogeneity, respectively.^[@R27]^ The pooled meta-analytic estimates should be interpreted with caution whenever *I*^2^ is \>50%. An *I*^2^ \>50% indicates that most of the observed differences between the study findings on the relation between IFN-γ ELISPOT and AR may be due to true underlying inconsistencies between study results rather than random variation.

Finally, the meta-analytic estimates of joined sensitivity and specificity were used to calculate positive predictive value (PPV) and negative predictive value (NPV) in each study population from the selected studies. Because PPV and NPV are functions not only of IFN-γ ELISPOT sensitivity and specificity but also of the population-specific incidence of AR, we did not report them as fixed numbers but rather as numbers varying with pretest risk of AR.

Similar analyses were performed to examine the secondary outcomes including the association between pretransplant IFN-γ ELISPOT and graft function, graft survival, and patient survival. We had planned to similarly analyze de novo DSA, but reported data in the studies were insufficient.

RESULTS
=======

Literature Search Results and Study Characteristics
---------------------------------------------------

A total of 584 potentially relevant citations were identified (EMBASE: 368; CENTRAL: 15; MEDLINE: 201). After the review of the titles and abstracts and the removal of duplicates, a total of 353 potentially eligible articles were identified. We excluded 335 studies for the following reasons: index test not evaluated (195 studies); insufficient data (lack of sufficient data to derive 2 × 2 tables or assess test performance in participants) or duplicate data (8 studies); different target population (hemodialysis patients, animal models) (59 studies); or studies using pretransplant IFN-γ ELISPOT for treatment decision purposes (1 study).^[@R12]^ The same procedure was followed for editorials, reviews, or comments (73 studies). We ultimately included 12 studies in our analyses (19 reports) with 1181 patients.^[@R10],[@R11],[@R14]-[@R20],[@R29]-[@R38]^ **Figure [1](#F1){ref-type="fig"}** shows the flow chart for study selection. All studies reported pretransplant donor-specific IFN-γ ELISPOT data and included a total of 1238 kidney transplant patients. The characteristics of the included studies are presented in **Table [1](#T1){ref-type="table"}**.

###### 

Study characteristics

![](txd-5-e451-g001)

![Flow of the studies reviewed.](txd-5-e451-g002){#F1}

Risk of Bias
------------

To evaluate the risk of bias, we followed the Hayden criteria.^[@R13]^ All the bias domains for all the studies are presented in **Table [2](#T2){ref-type="table"}**.

###### 

Risk of bias of the included studies based on the Hayden criteria

![](txd-5-e451-g003)

In general, there was an overall low risk of bias in all the domains. The relationship between the PF and outcome may have differed between participants and eligible nonparticipants in 2 studies. In the study by Augustine,^[@R14]^ there was no information about the sampling frame and recruitment. The authors of the study by Kim^[@R19]^ did not specify the place of recruitment. We found a high risk of bias in 1 study, as the authors did not give any information about the period and place of recruitment^[@R20]^ and in another^[@R29]^ because there was an early interruption with high incidence of rejections in the tacrolimus withdrawal arm. This reason made us consider also a moderate risk of bias due to presence of differences between participants who completed the study and those who did not.

The methods and setting of measurement of the PF in our meta-analysis (pretransplant IFN-γ ELISPOT) were not the same for all study participants, and that brought a moderate risk of bias in 3 studies.^[@R11],[@R12],[@R16]^ The method of imputation used for missing PF data was not correct and gave another study a high risk of bias.^[@R11]^ The outcome measurement was of low risk of bias for all studies except for 1^[@R11]^ that presents a high risk of bias in the method and setting of outcome measurement, which was not the same for all study participants.

Acute Rejection
---------------

Out of the 1181 included kidney transplant recipients, 209 (18%) developed AR, with an incidence ranging between 8% and 44% in each study. Pretransplant donor-specific IFN-γ ELISPOT was positive in 512 (43%) of the patients and ranged between 25% and 88% in each study.

Positive pretransplant IFN-γ ELISPOT was associated with a significantly high risk of AR (odds ratio 3.29; 95% confidence interval (CI), 2.34-4.60) (**Figure [2](#F2){ref-type="fig"}** and **Figure S1, SDC**, <http://links.lww.com/TXD/A207>). Pooled sensitivity and specificity for AR, jointly estimated via the hierarchical summary ROC model, were 64.9% (95% CI, 53.7%-74.6%) and 65.8% (95% CI, 57.3%-73.5%). The joint sensitivity and specificity estimates resulted in a positive likelihood ratio and a negative likelihood ratio of 1.90 (95% CI, 1.58-2.28) and 0.53 (95% CI, 0.42-0.68), respectively. Because the values of positive likelihood ratio below 2.0 and negative likelihood ratio above 0.5 are generally regarded as reflecting limited prognostic ability, our findings indicate that the added value of pretransplant IFN-γ ELISPOT to predict AR at the individual level is at the edge of being significant.^[@R39]^ Notably, results of the joined meta-analysis of sensitivity and specificity and the associated summary ROC curve showed a certain degree of heterogeneity across studies (Figure [3](#F3){ref-type="fig"} and **Figure S2, SDC**, <http://links.lww.com/TXD/A207>).

![Forest plot of analysis acute rejection (AR).](txd-5-e451-g004){#F2}

![HSROC plot of analysis of acute rejection, namely joined meta-analysis of sensitivity and specificity and associated summary ROC curve concerning the predictive power of IFNγ ELISPOT for acute rejection, based on the fitted hierarchical logistic regression model. The graph shows the pooled summaries, together with circles showing the individual study estimates; the solid line represents the estimate of the summary ROC curve, and the square symbol represents a summary value for sensitivity and specificity of 64.9% (95% CI, 53.7-74.6) and 65.8% (95% CI: 57.4-73.5), respectively. The dotted green line represents the 95% confidence region for the summary operating point (ie, every sensitivity/specificity value lying within the region delimited by the green line must be regarded as not significantly different from our pooled estimate, at 5% significance level). The dotted orange line represents the 95% prediction region (confidence region for a forecast of the true sensitivity and specificity in a future study). The shape of the prediction region is dependent on the assumption of a bivariate normal distribution for the random effects included in the statistical model. It should therefore not be overinterpreted; it is intended to give a visual representation of the extent of between-study heterogeneity. CI, confidence interval; HSROC, hierarchical summary receiver-operating characteristic; IFN-γ, interferon-γ enzyme-linked immunospot; ROC, receiver operating characteristic.](txd-5-e451-g005){#F3}

To test whether differences across studies concerning sensitivity and specificity could be explained by differences in the characteristics of the study populations such as the type of induction therapy, ethnicity, and geographical area, and also to identify patient categories in which pretransplant IFN-γ ELISPOT could be most useful, we performed metaregression analyses (Figure [4](#F4){ref-type="fig"} and **Figures S3 and S4, SDC**, <http://links.lww.com/TXD/A207>). After adjusting for multiple testing to prevent spurious findings, metaregression models did not show evidence that thymoglobulin induction, recipient black ethnicity, living versus deceased donors, or geographical location affected sensitivity or specificity, but publication year was the only variable with a significant inverse association with specificity (*P* = 0.021).

![Relationship between sensitivity or specificity and the prevalence of thymoglobulin use (A), the prevalence of African Americans (AAs) (B), the publication year (C) of each study, estimated by random-effects meta-analysis (ie, metaregression). The size of the circles is proportional to the weight of each study, which is inversely proportional to the study variance. The variance is calculated as the sum of the within- and the between-study variances; therefore, it is not only dependent on the size of the study population. Sensitivity and specificity values on y-axis are obtained from backtransformation of the logit values; therefore, the scale of the y-axis is not linear. At the bottom of the graph are reported predictions based on the fitted model, for example, what would have happened to sensitivity or specificity if the prevalence of thymoglobulin use in the study population had been 0% or 100% (A); if the prevalence of AA had been 0% or 100% (B); and if the publication year of the studies had been 2005 for all studies or 2015 for all studies (C). Each figure reports the nominal *P* value using the default Knapp-Hartung variance estimator, testing that the regression slope is significantly different from zero. However, statistical inference mentioned in the text was not based on those nominal *P* values but rather on adjustment for multiple testing using Monte Carlo permutation test based on the methodology proposed by Higgins and Thompson. The *I*^2^ represents the proportion of the variance between studies, which is due to unmeasured heterogeneity between studies rather than chance or difference in the variable on the x-axis of the plot. IFN-γ ELISPOT, interferon-γ enzyme-linked immunospot.](txd-5-e451-g006){#F4}

We used the joint meta-analytic estimates of sensitivity and specificity to calculate PPV and NPV in each study population from the 12 selected studies. As a consequence of the fact that the study populations differed greatly with regard to the incidence of AR, PPV was rather low, ranging between 16% and 60%, whereas NPV was significantly higher and ranged between 70% and 95% (Figure [5](#F5){ref-type="fig"} and Table [3](#T3){ref-type="table"}), respectively. In studies where the risk of AR was 16% or lower---which is the case of most transplant centers nowadays---a negative pretransplant IFN-γ ELISPOT implied an NPV of 91% or higher (ie, a predicted risk of AR of 9% or lower).

###### 

Positive and negative predictive values of acute rejection
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![Positive and negative predictive values of IFNγ ELISPOT as a function of the incidence of AR in the study population. Because positive and negative predictive values are not fixed numbers but rather numbers varying with the incidence of AR in the study population, the plot shows on the y-axis how positive or negative predictive values (ie, posttest AR risk) change according to different values of the incidence of AR in the study population (ie, pretest AR risk) reported on x-axis. To visualize how pretest probability changes with the result of IFN-γ ELISPOT, draw a vertical line from a chosen pretest probability of AR on the x-axis until it hits the red curve if IFN-γ ELISPOT is positive, or the green curve if IFN-γ ELISPOT is negative, and read the resulting posttest probability of AR on the y-axis. Cross-marks and associated labels represent the positive and negative predictive values that would result from each study, based on the study-specific incidence of AR of and the overall joined meta-analytic estimate of sensitivity and specificity. AR, acute rejection; IFN-γ ELISPOT, interferon-γ enzyme-linked immunospot.](txd-5-e451-g008){#F5}

Graft Function
--------------

Six- and 12-month serum creatinine and eGFR were similar between patients with positive or negative pretransplant IFN-γ ELISPOT (weighted mean differences for serum creatinine at 6 and 12 months were as follows: 1.24 mg/dL \[−0.72, 3.2\], *P* = 0.22 and 0.38 mg/dL \[−0.27, 1.04\], *P* = 0.25, respectively; weighted mean difference for eGFR at 6 and 12 months were as follows: −0.97 \[−2.07, 0.13\], *P* = 0.08 and −0.49 \[−1.27, 0.28\], *P* = 0.21, respectively). However, there was a high heterogeneity between the 2 studies meta-analyzed (*I*^2^ \> 75%) (Figures [6](#F6){ref-type="fig"} and **[7](#F7){ref-type="fig"}**).

![Forest plot of serum creatinine (mg/dL) at 6 (A) and 12 months (B). CI, confidence interval; SD, standard deviation.](txd-5-e451-g009){#F6}

![Forest plot of eGFR at 6 (A) and 12 months (B). CI, confidence interval; eGFR, estimated glomerular filtration rate; SD, standard deviation.](txd-5-e451-g010){#F7}

Graft and Patient Survival
--------------------------

The very limited number of studies assessing the impact of the pretransplant IFN-γ ELISPOT on graft loss or patient survival did not allow us to perform a meta-analysis on these outcomes. The pooled sensitivity and specificity of pretransplant IFN-γ ELISPOT for both 1-year patient and graft survival prediction are shown in Figures [8](#F8){ref-type="fig"} and [9](#F9){ref-type="fig"}.

![Forest plot of graft loss censored for death at 1 year. CI, confidence interval.](txd-5-e451-g011){#F8}

![Forest plot of analysis of all causes of death at 1 year. CI, confidence interval.](txd-5-e451-g012){#F9}

DISCUSSION
==========

To the best of our knowledge, this is the first meta-analysis to date investigating the association between pretransplant donor-specific IFN-γ ELISPOT and graft outcomes in kidney transplant recipients. The data show that pretransplant donor-specific IFN-γ ELISPOT is significantly associated with a higher risk of AR. Notably, and although the predictive values of the assay vary depending on the incidence of AR in each study, the NPV of this assay is consistently high (ie, \>90%), particularly in low-risk populations (ie, with AR risk ≤16%). Moreover, and based on our regression analyses on aggregate data, the performance of the assay in predicting graft outcomes seems not to be strongly affected by study population characteristics. We found an apparent trend of specificity to decrease in the years, although we could not infer whether this association was related to unmeasured confounding variables or simply represented a random finding.

Today, the assessment of the immunologic risk in organ transplant recipients before transplantation is exclusively done by the assessment of donor/recipient HLA mismatch and the presence of preformed circulating anti-HLA antibodies,^[@R3]^ with the assumption that the humoral allosensitization also illustrates the allospecific cellular immune response. However, it is well known that cellular memory may occur without humoral activation and is a key factor in initiating and mediating allograft rejection.^[@R40]-[@R43]^ In fact, experimental studies in mice have shown that alloreactive memory T cells play a major pathogenic role in allograft rejection, therefore measuring these cells in a functional manner has been proposed as a strategy to estimate the risk of AR, especially TCMR. The IFN-γ ELISPOT has been developed to measure the frequency of alloreactive memory IFN-γ-producing T cells at the single cell level.^[@R44],[@R45]^ While initial studies showed a clear association between pretransplant IFN-γ ELISPOT positivity and risk of AR,^[@R8],[@R18]^ subsequent larger studies challenged this association, especially in subjects receiving T-cell-depleting induction therapy with thymoglobulin.^[@R10]-[@R12]^

Overall, the present meta-analysis confirms a significant association between pretransplant donor-specific IFN-γ ELISPOT and higher risk of AR, particularly among those patients not receiving T-cell-depleting induction therapy. Though the accuracy to predict AR at the individual level is suboptimal, the high NPV (\>90%) of this assay suggests that it could be used to identify patients at low risk of AR. Therefore, pretransplant donor-specific IFN-γ ELISPOT seems to represent an important tool to measure baseline cellular risk stratification in kidney transplant recipients before transplant surgery and eventually allow immunosuppressive therapy titration accordingly. However, additional biomarkers need to be developed and optimized to better estimate the immunological risk of subjects at the time of kidney transplant. In this regard, as calcineurin inhibitors (CNI) are a key to effectively inhibiting T-cell activation and proliferation, markers accurately identifying patients with suboptimal tacrolimus pharmacokinetics could potentially add value for better patient T-cell immune risk stratification. Likewise, the value of this assay in patients receiving CNI-free immunosuppressive strategies such as costimulation blockade-based regimens needs further investigation.

Our meta-analysis focused on pretransplant donor-specific IFN-γ ELISPOT. Only few studies addressed the utility of serial ELISPOT measurements to detect subclinical AR, predict development of DSA, or graft dysfunction. Data from a prospective cohort study indicate that posttransplant measurements of donor-reactive memory T cells by IFN-γ ELISPOT assay can identify, within kidney transplant patients with stable renal function, patients with minimal risk of having concurrent or future intragraft infiltrates.^[@R17]^ Likewise, a nonrandomized interventional study showed that prospective evaluation of donor-specific T-cell sensitization by IFN-γ ELISPOT may add important information on the alloimmune state of transplanted patients to be used in daily clinical practice.^[@R12]^ However, more studies are needed to address whether IFN-γ ELISPOT-driven immunosuppression provides better outcomes than standard, protocol-based clinical management. Two ongoing multicentric, randomized biomarker-driven trials are testing the utility of pretransplant IFN-γ ELISPOT (NCT02540395; NCT03465397) to personalize immunosuppression.

Limitations and Strengths
-------------------------

Our study should be interpreted in light of some limitations. Although we performed an exhaustive search of the literature for pretransplant donor-specific IFN-γ ELISPOT, publication bias cannot be ruled out. It is possible that smaller negative studies have not been published. Another important limitation is the variability in the standard operating procedure used for the IFN-γ ELISPOT. The fact that pretransplant ELISPOT has only been standardized across a relatively small number of centers^[@R6],[@R7]^ may, at least in part, explain the heterogeneity across the different studies. Additional limitations include the relatively low number of patients included in the analysis and the use of aggregate as opposed to individual level data; therefore, the statistical power may be inadequate for drawing definitive conclusions about the ability of pretransplant donor-specific IFN-γ ELISPOT to predict in different patient categories such as in patients receiving T-cell depletion induction or among those not receiving CNI-based immunosuppression.

The strengths of this analysis comprise the inclusion of a fairly large number of studies from different continents, which included a wide spectrum of patient categories. Nonetheless, our findings on test performance were reasonably consistent across the different studies.

CONCLUSIONS
===========

In summary, this meta-analysis shows that in low-risk kidney transplant populations a negative pretransplant donor-specific IFN-γ ELISPOT is associated with a very low probability of AR. Although the prediction of AR at the individual level is suboptimal, this assay could be used, in concert with others, for treatment decision purposes in low-risk populations. Importantly, prospective, randomized, biomarker-driven trials using the IFN-γ ELISPOT assay are warranted.
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